Drug Trial Radar · NCT05161936
A Study to Evaluate Lumasiran in Adults With Recurrent Calcium Oxalate Kidney Stone Disease and Elevated Urinary Oxalate Levels
Last checked: Nov 20, 2026Latest source record: May 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
2
Actual
Start
Jan 27, 2022
Primary completion
Nov 1, 2022
Study completion Nov 1, 2022
Sponsor
- Lead sponsor
- Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
- Sponsor type
- Industry
- First posted
- Dec 17, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to evaluate the effect of lumasiran on the percent change in urinary oxalate excretion in patients with recurrent calcium oxalate kidney stone disease.
Conditions
- Recurrent Calcium Oxalate Kidney Stone Disease
- Elevated Urinary Oxalate Levels
Interventions
LumasiranDrug
Lumasiran will be administered by SC injection.
PlaceboDrug
Placebo will be administered by SC injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change in 24-hour Urinary Oxalate From Baseline to Month 6Time frame: Baseline to Month 6
Locations
31 sites in 6 countries. Site status is shown where the registry gives one.
Clinical Trial Site
Birmingham, Alabama
Clinical Trial Site
Northridge, California
Clinical Trial Site
San Francisco, California
Clinical Trial Site
Hialeah, Florida
Clinical Trial Site
Acworth, Georgia
Clinical Trial Site
Quincy, Illinois
Clinical Trial Site
Carmel, Indiana
Clinical Trial Site
Boston, Massachusetts
Clinical Trial Site
Edina, Minnesota
Clinical Trial Site
Rochester, Minnesota
Clinical Trial Site
Las Vegas, Nevada
Clinical Trial Site
Albany, New York
Clinical Trial Site
Garden City, New York
Clinical Trial Site
Greensboro, North Carolina
Clinical Trial Site
North Charleston, South Carolina
Clinical Trial Site
El Paso, Texas
Clinical Trial Site
Houston, Texas
Clinical Trial Site
Brussels, Belgium
Clinical Trial Site
Ghent, Belgium
Clinical Trial Site
Kortrijk, Belgium
Clinical Trial Site
Liège, Belgium
Clinical Trial Site
Bologna, Italy
Clinical Trial Site
Pavia, Italy
Clinical Trial Site
Rome, Italy
Clinical Trial Site
Verona, Italy
Clinical Trial Site
Madrid, Spain
Clinical Trial Site
Bern, Switzerland
Clinical Trial Site
Lausanne, Switzerland
Clinical Trial Site
Zurich, Switzerland
Clinical Trial Site
Doncaster, United Kingdom
Clinical Trial Site
Leeds, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.